Ongusaha PP, et al. (2008) Identification of ROCK1 as an upstream activator of the JIP-3 to JNK signaling axis in response to UVB damage. Sci Signal 1, ra14 19036714

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T202-p - ERK1 (human) ▲

Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  bone cancer Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes UV increase UV ROCK1 (human) no effect upon treatment-induced increase ROCK1 siRNA-no effect

Y204-p - ERK1 (human) ▲

Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene Orthologous residues ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  bone cancer Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes UV increase UV ROCK1 (human) no effect upon treatment-induced increase ROCK1 siRNA-no effect

T185-p - ERK2 (human) ▲

Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  bone cancer Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes UV increase UV ROCK1 (human) no effect upon treatment-induced increase ROCK1 siRNA-no effect

Y187-p - ERK2 (human) ▲

Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene Orthologous residues ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  bone cancer Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes UV increase UV ROCK1 (human) no effect upon treatment-induced increase ROCK1 siRNA-no effect

S139-p - H2AX (human) ▲

Modsite: GkkAtQAsQEy____ SwissProt Entrez-Gene Orthologous residues H2AX (human): S139‑p, H2AX (mouse): S139‑p, H2AX (rat): S139‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  bone cancer Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes UV increase Y27632 UV inhibit treatment-induced increase

S314-p - JIP3 (human) ▲

Modsite: RAREKRDsRNMEVQV SwissProt Entrez-Gene Orthologous residues JIP3 (human): S314‑p, JIP3 (mouse): S315‑p, JIP3 iso2 (mouse): S283‑p, JIP3 iso3 (mouse): S292‑p, JIP3 (rat): S315‑p Characterization Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry (in vitro), western blotting Disease tissue studied:  cancer, squamous cell carcinoma Relevant cell lines - cell types - tissues:  SCC28 (squamous) Cellular systems studied:  cell lines Enzymes shown to modify site in vitro:  Type Enzyme KINASE ROCK1 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE ROCK1 (human) pharmacological inhibitor of upstream enzyme, activation of upstream enzyme, co-immunoprecipitation

S364-p - JIP3 (human) ▲

Modsite: TRLDRtGssPTQGIV SwissProt Entrez-Gene Orthologous residues JIP3 (human): S364‑p, JIP3 (mouse): S365‑p, JIP3 iso2 (mouse): S333‑p, JIP3 iso3 (mouse): S342‑p, JIP3 (rat): S365‑p Characterization Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry (in vitro), western blotting Disease tissue studied:  cancer, squamous cell carcinoma Relevant cell lines - cell types - tissues:  SCC28 (squamous) Cellular systems studied:  cell lines Enzymes shown to modify site in vitro:  Type Enzyme KINASE ROCK1 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE ROCK1 (human) pharmacological inhibitor of upstream enzyme, activation of upstream enzyme, co-immunoprecipitation

S365-p - JIP3 (human) ▲

Modsite: RLDRtGssPTQGIVN SwissProt Entrez-Gene Orthologous residues JIP3 (human): S365‑p, JIP3 (mouse): S366‑p, JIP3 iso2 (mouse): S334‑p, JIP3 iso3 (mouse): S343‑p, JIP3 (rat): S366‑p Characterization Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry (in vitro), western blotting Disease tissue studied:  cancer, squamous cell carcinoma Relevant cell lines - cell types - tissues:  SCC28 (squamous) Cellular systems studied:  cell lines Enzymes shown to modify site in vitro:  Type Enzyme KINASE ROCK1 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE ROCK1 (human) pharmacological inhibitor of upstream enzyme, activation of upstream enzyme, co-immunoprecipitation

T183-p - JNK1 (human) ▲

Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene Orthologous residues JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  bone cancer Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes UV increase UV ROCK1 (human) increase ROCK1 siRNA inhibits UV JIP3 (human) increase JIP3 siRNA inhibits Y27632 UV inhibit treatment-induced increase ROCK1 (human) increase ROCK1 (human) ROCK1 (human) augment treatment-induced increase constitutively active ROCK1

Y185-p - JNK1 (human) ▲

Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene Orthologous residues JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  bone cancer Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes UV increase UV ROCK1 (human) increase ROCK1 siRNA inhibits UV JIP3 (human) increase JIP3 siRNA inhibits Y27632 UV inhibit treatment-induced increase ROCK1 (human) increase ROCK1 (human) ROCK1 (human) augment treatment-induced increase constitutively active ROCK1

T183-p - JNK2 (human) ▲

Modsite: ACtNFMMtPyVVtRY SwissProt Entrez-Gene Orthologous residues JNK2 (human): T183‑p, JNK2 iso2 (human): T183‑p, JNK2 iso3 (human): T183‑p, JNK2 (mouse): T183‑p, JNK2 (rat): T183‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  bone cancer Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes UV increase UV ROCK1 (human) increase ROCK1 siRNA inhibits UV JIP3 (human) increase JIP3 siRNA inhibits Y27632 UV inhibit treatment-induced increase ROCK1 (human) increase ROCK1 (human) ROCK1 (human) augment treatment-induced increase constitutively active ROCK1

Y185-p - JNK2 (human) ▲

Modsite: tNFMMtPyVVtRYYR SwissProt Entrez-Gene Orthologous residues JNK2 (human): Y185‑p, JNK2 iso2 (human): Y185‑p, JNK2 iso3 (human): Y185‑p, JNK2 (mouse): Y185‑p, JNK2 (rat): Y185‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  bone cancer Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes UV increase UV ROCK1 (human) increase ROCK1 siRNA inhibits UV JIP3 (human) increase JIP3 siRNA inhibits Y27632 UV inhibit treatment-induced increase ROCK1 (human) increase ROCK1 (human) ROCK1 (human) augment treatment-induced increase constitutively active ROCK1

S63-p - Jun (human) ▲

Modsite: kNsDLLtsPDVGLLk SwissProt Entrez-Gene Orthologous residues Jun (human): S63‑p, Jun (mouse): S63‑p, Jun (rat): S63‑p, Jun (cow): S63‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  bone cancer Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes UV increase Y27632 UV inhibit treatment-induced increase ROCK1 (human) increase ROCK1 (human) ROCK1 (human) augment treatment-induced decrease constitutively active

S73-p - Jun (human) ▲

Modsite: VGLLkLAsPELERLI SwissProt Entrez-Gene Orthologous residues Jun (human): S73‑p, Jun (mouse): S73‑p, Jun (rat): S73‑p, Jun (cow): S73‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  bone cancer Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes UV increase Y27632 UV inhibit treatment-induced increase ROCK1 (human) increase ROCK1 (human) ROCK1 (human) augment treatment-induced decrease constitutively active

T19-p - MRLC2 (human) ▲

Modsite: KKRPQRAtsNVFAMF SwissProt Entrez-Gene Orthologous residues MRLC2 (human): T19‑p, MRLC2 (mouse): T19‑p, MRLC2 (rat): T19‑p, MRLC2 (cow): T19‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  bone cancer Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes ROCK1 (human) increase ROCK1 (human) ROCK1 (human) augment treatment-induced decrease constitutively active

S20-p - MRLC2 (human) ▲

Modsite: KRPQRAtsNVFAMFD SwissProt Entrez-Gene Orthologous residues MRLC2 (human): S20‑p, MRLC2 (mouse): S20‑p, MRLC2 (rat): S20‑p, MRLC2 (cow): S20‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  bone cancer Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes ROCK1 (human) increase ROCK1 (human) ROCK1 (human) augment treatment-induced decrease constitutively active

T180-p - P38A (human) ▲

Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene Orthologous residues P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  bone cancer Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes UV increase UV ROCK1 (human) no effect upon treatment-induced increase ROCK1 siRNA-no effect

Y182-p - P38A (human) ▲

Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene Orthologous residues P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  bone cancer Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes UV increase UV ROCK1 (human) no effect upon treatment-induced increase ROCK1 siRNA-no effect

S139-p - H2AX (mouse) ▲
Modsite: GkKAsQAsQEy____ SwissProt Entrez-Gene Orthologous residues H2AX (human): S139‑p, H2AX (mouse): S139‑p, H2AX (rat): S139‑p Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes ROCK1 (human) increase HA-1077 ROCK1 (human) inhibit treatment-induced increase

T183-p - JNK1 (mouse) ▲

Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene Orthologous residues JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes ROCK1 (human) increase HA-1077 ROCK1 (human) inhibit treatment-induced increase

Y185-p - JNK1 (mouse) ▲

Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene Orthologous residues JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes ROCK1 (human) increase HA-1077 ROCK1 (human) inhibit treatment-induced increase

T183-p - JNK2 (mouse) ▲

Modsite: ACTNFMMtPyVVtRY SwissProt Entrez-Gene Orthologous residues JNK2 (human): T183‑p, JNK2 iso2 (human): T183‑p, JNK2 iso3 (human): T183‑p, JNK2 (mouse): T183‑p, JNK2 (rat): T183‑p Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes ROCK1 (human) increase HA-1077 ROCK1 (human) inhibit treatment-induced increase

Y185-p - JNK2 (mouse) ▲

Modsite: TNFMMtPyVVtRYYR SwissProt Entrez-Gene Orthologous residues JNK2 (human): Y185‑p, JNK2 iso2 (human): Y185‑p, JNK2 iso3 (human): Y185‑p, JNK2 (mouse): Y185‑p, JNK2 (rat): Y185‑p Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes ROCK1 (human) increase HA-1077 ROCK1 (human) inhibit treatment-induced increase